ABSTRACT Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder treated with complement C5 inhibitors. While eculizumab (Ecu) has documented safety in pregnancy, data on ravulizumab (Rav) are scarce. We report a 25‐year‐old woman with PNH who experienced inadvertent Rav exposure at 8 weeks of pregnancy before switching to Ecu. Despite requiring transfusions, she delivered a healthy infant at term without anomalies or thrombosis. This case represents one of the earliest reports of Rav use in pregnancy, suggesting potential safety. Further data are needed, and multidisciplinary management remains essential for pregnant patients with PNH. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Morioka et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: